The final, formatted version of the article will be published soon.
REVIEW article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1425212
This article is part of the Research Topic Single-Cell Sequencing of the Immune Microenvironment in Cancer View all 3 articles
Single-cell RNA sequencing in endometrial cancer: exploring the epithelial cells and the microenvironment landscape
Provisionally accepted- 1 “Contigo Contra el Cáncer de la Mujer” Foundation, Madrid, Spain
- 2 Foundation for Biomedical Research of Ramón y Cajal University Hospital, Madrid, Madrid, Spain
- 3 Centre for Biomedical Research in Cancer Networks (CIBERONC), Carlos III Health Institute (ISCIII), Madrid, Spain
- 4 Department of Anatomical Pathology, Ramon y Cajal University Hospital, Madrid, Asturias, Spain
- 5 Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, Madrid, Spain
- 6 International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron-salud Group, Barcelona, Spain
- 7 Medica Scientia Innovation Research (MedSIR), Barcelona, Catalonia, Spain
- 8 Medica Scientia Innovation Research, Ridgewood, United States
- 9 Faculty of Biomedical Sciences and Health, European University of Madrid, Madrid, Madrid, Spain
- 10 IOB Institute of Oncology Madrid, Hospital Beata María Ana de Jesús, Madrid, Spain
Single-cell RNA sequencing (scRNA-seq) technology has emerged as a powerful tool for dissecting cellular heterogeneity and understanding the intricate biology of diseases, including cancer. Endometrial cancer (EC) stands out as the most prevalent gynecological malignancy in Europe and the second most diagnosed worldwide, yet its cellular complexity remains poorly understood. In this review, we explore the contributions of scRNA-seq studies to shed light on the tumor cells and cellular landscape of EC. We discuss the diverse tumoral and microenvironmental populations identified through scRNA-seq, highlighting the implications for understanding disease progression. Furthermore, we address potential limitations inherent in scRNA-seq studies, such as technical biases and sample size constraints, emphasizing the need for larger-scale research encompassing a broader spectrum of EC histological subtypes. Notably, a significant proportion of scRNA-seq analyses have focused on primary endometrioid carcinoma tumors, underscoring the need to incorporate additional histological and aggressive types to comprehensively capture the heterogeneity of EC.
Keywords: single-cell RNA sequencing1, endometrial cancer2, tumor microenvironment3, immune landscape4, cellular heterogeneity5
Received: 29 Apr 2024; Accepted: 06 Aug 2024.
Copyright: © 2024 González-Martínez, Pérez-Mies, Cortés and Palacios. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
José Palacios, Foundation for Biomedical Research of Ramón y Cajal University Hospital, Madrid, Madrid, Spain
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Belén Pérez-Mies
2,3,4,5